OAM
APLS

Oxford Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Oxford Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-25,610
Closed -$338K – 1643
2018
Q4 		$338K Buy
+25,610
New +$393K 0.01% 1353
2018
Q1 		– Sell
-51,670
Closed -$1.12M – 1592
2017
Q4 		$1.12M Buy
+51,670
New +$761K 0.02% 880

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Oxford Asset Management's APLS Position: Q1 2019 in Review

Oxford Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2019, closing a stake of 25,610 shares — an estimated $338K sold.

Oxford Asset Management first reported a position in APLS in Q4 2017 and held it in 2 quarters. The position peaked at $1.12M in Q4 2017. 92 funds tracked by Wall St. Rank hold APLS as of Q1 2019.

  • Oxford Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 25,610 Apellis Pharmaceuticals shares in Q1 2019, an estimated $338K.
  • Oxford Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Oxford Asset Management's Apellis Pharmaceuticals position peaked at $1.12M in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.